Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

Herpes Labialis Clinical Trial

— P2a  

Official title:

A Phase 2, Multi-site, Randomized, Double-blind, Vehicle-controlled Study of the Efficacy and Safety of Squaric Acid Dibutyl Ester (SADBE) in Subjects With Recurrent Herpes Labialis - Single Versus Two-dose Arm Application

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02965781
• Other study ID #: P2a
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2016
• Est. completion date: December 20, 2018

Study information

• Verified date: October 2021
• Source: Squarex, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and efficacy of SADBE in the prevention of recurrent herpes labialis in adults. Two-thirds of the participants will receive a SADBE solution, while the other third will receive only the vehicle as a placebo control. The solutions will be administered topically to the patient's arms. The study will compare a single-arm application versus a two-arm application versus two placebo doses on the arm.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 139
• Est. completion date: December 20, 2018
• Est. primary completion date: December 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18

• Clinical diagnosis of herpes labialis, which may be made at the screening visit based on the patient's self-reported history of symptoms. An active herpes labialis outbreak at the time of entry into the clinical trial will neither be required nor will be an exclusion criteria.

• Self report having four or more episodes of herpes labialis in the past 12 months

Exclusion Criteria:

• People that have had treatment with anti viral therapy within 2 weeks before sensitization dose.

• Pregnant or lactating females.

• Current or recurrent non-herpetic infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection.

• Therapy with glucocorticoid or immunosuppressants at time of recruitment or within past 4 weeks, except for inhaled corticosteroids for asthma or topical steroids in sites other than face.

• History of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers)

• History of organ transplantation

• HIV-positive status determined by history at screening or known history of any other immunosuppressive disease.

• Severe co-morbidities (diabetes mellitus requiring insulin, CHF (EF<50% at baseline will be exclusionary) MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease

• History of exposure to squaric acid or squaric acid dibutyl ester.

• Known hypersensitivity to DMSO

• Any condition judged by the investigator to cause this clinical trial to be detrimental to the patient.

• Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.

• Previous or current participation in a clinical trial of SADBE to treat herpes labialis.

Related Conditions & MeSH terms

• Cold Sore
• Herpes Labialis

Intervention

Drug:
• SADBE
Topical solution

Other:
• Placebo
Topical solution

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Advantage Clinical Trials	Bronx	New York
United States	International Research Partners, LLC	Doral	Florida
United States	Quality Clinical Research, Inc	Omaha	Nebraska
United States	Stanford Medicine Outpatient Center	Redwood City	California

Sponsors (1)

Lead Sponsor	Collaborator
Squarex, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose	The number of days until a patient reports his or her first new herpes labialis episode from 43 - 121 days following the first dose	43 - 121 days after the first dose
Secondary	Number of Outbreaks Beginning 43 Days After the First Dose up to 12 Months	The number of new herpes labialis episodes per subject during the 12-month follow up period following the first drug dose, beginning day 43 after the first dose	From day 43 after the first dose up to 12 months